

NCT01888965 Raw comparison:

Summary:
CHIA has 26 criteria while your personal folder has 27 criteria
Total found criteria: 26/26
Total not Found: 0/26
Total Extra: 1
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Patients with a confirmed diagnosis of             │ Patients with a confirmed diagnosis of             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Stage 4 colon cancer either s/p metastasectomy or  │ Stage 4 colon cancer either s/p metastasectomy or  │
│ post-initial chemotherapy or maintenance "standard │ post-initial chemotherapy or maintenance "standard │
│ of care" either involving                          │ of care" either involving                          │
│ 5-fluorouracil/leucovorin (5-FU/LV) alone or       │ 5-fluorouracil/leucovorin (5-FU/LV) alone or       │
│ continual bevacizumab alone Patients in            │ continual bevacizumab alone Patients in            │
│ maintenance cohort must have had 2 consecutive CT  │ maintenance cohort must have had 2 consecutive CT  │
│ scans showing stable disease and not be            │ scans showing stable disease and not be            │
│ experiencing significant prior treatment-related   │ experiencing significant prior treatment-related   │
│ toxicity above Grade 1                             │ toxicity above Grade 1                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pancreas cancer either s/p resection and adjuvant  │ Pancreas cancer either s/p resection and adjuvant  │
│ chemotherapy or locally advanced pancreas cancer   │ chemotherapy or locally advanced pancreas cancer   │
│ s/p chemotherapy and radiation Initial             │ s/p chemotherapy and radiation Initial             │
│ chemotherapy or radiation therapy may have been    │ chemotherapy or radiation therapy may have been    │
│ stopped between 2 weeks and 2 months prior to      │ stopped between 2 weeks and 2 months prior to      │
│ study start and patients must have recovered from  │ study start and patients must have recovered from  │
│ prior treatment related toxicity to grade 1 or     │ prior treatment related toxicity to grade 1 or     │
│ less                                               │ less                                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Prior surgery including tumor resection or         │ Prior surgery including tumor resection or         │
│ metastasectomy must have been performed at least 4 │ metastasectomy must have been performed at least 4 │
│ weeks prior to study enrollment                    │ weeks prior to study enrollment                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ No concomitant anti-cancer treatment is allowed    │ No concomitant anti-cancer treatment is allowed    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Age >/= 18 years                                   │ Age \>/= 18 years                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Performance status of 0-1                          │ Performance status of 0-1                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Adequate hepatic bone marrow and renal function    │ Adequate hepatic bone marrow and renal function    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Partial thromboplastin time (PTT) must be </= 1 5  │ Partial thromboplastin time (PTT) must be \</= 1 5 │
│ x upper normal limit of institution's normal range │ x upper normal limit of institution's normal range │
│ and INR (International Normalized Ratio) < 1 5     │ and INR (International Normalized Ratio) \< 1 5    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Life expectancy >/= 4 months for maintenance       │ Life expectancy \>/= 4 months for maintenance      │
│ cohorts and >/= 6 months for adjuvant cohorts      │ cohorts and \>/= 6 months for adjuvant cohorts     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women of childbearing potential must have a        │ Women of childbearing potential must have a        │
│ negative serum pregnancy test within 14 days prior │ negative serum pregnancy test within 14 days prior │
│ to initiation of treatment and must not be         │ to initiation of treatment and must not be         │
│ lactating                                          │ lactating                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subject is capable of understanding and complying  │ Subject is capable of understanding and complying  │
│ with protocol demands and able to sign and date    │ with protocol demands and able to sign and date    │
│ the informed consent                               │ the informed consent                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women of child-bearing potential who are           │ Women of child-bearing potential who are           │
│ biologically able to conceive not employing two    │ biologically able to conceive not employing two    │
│ forms of highly effective contraception or who are │ forms of highly effective contraception or who are │
│ pregnant                                           │ pregnant                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Women who are breast-feeding                       │ Women who are breast-feeding                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Fertile males unwilling to use contraception       │ Fertile males unwilling to use contraception       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with brain metastases or any history of   │ Patients with brain metastases or any history of   │
│ brain metastases                                   │ brain metastases                                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients who have undergone major surgery (e g     │ Patients who have undergone major surgery (e g     │
│ intra-thoracic -abdominal or -pelvic) </= 4 weeks  │ intra-thoracic -abdominal or -pelvic) \</= 4 weeks │
│ prior to starting study treatment or who have not  │ prior to starting study treatment or who have not  │
│ recovered from such therapy                        │ recovered from such therapy                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with a history of pulmonary embolism or   │ Patients with a history of pulmonary embolism or   │
│ untreated deep vein thrombosis within the past 6   │ untreated deep vein thrombosis within the past 6   │
│ months                                             │ months                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Impairment of gastrointestinal (GI) function or GI │ Impairment of gastrointestinal (GI) function or GI │
│ disease that may significantly alter the           │ disease that may significantly alter the           │
│ absorption of dovitinib                            │ absorption of dovitinib                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ The subject has had another active malignancy      │ The subject has had another active malignancy      │
│ within the past 5 years except for cervical cancer │ within the past 5 years except for cervical cancer │
│ in situ in situ carcinoma of the bladder or non-   │ in situ in situ carcinoma of the bladder or non-   │
│ melanoma carcinoma of the skin                     │ melanoma carcinoma of the skin                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients who have received the last administration │ Patients who have received the last administration │
│ of an anticancer therapy including chemotherapy    │ of an anticancer therapy including chemotherapy    │
│ immunotherapy hormonal therapy and monoclonal      │ immunotherapy hormonal therapy and monoclonal      │
│ antibodies </= 2 weeks prior to starting the study │ antibodies \</= 2 weeks prior to starting the      │
│ drug or who have not recovered from the side       │ study drug or who have not recovered from the side │
│ effects of such therapy                            │ effects of such therapy                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Cirrhosis chronic active hepatitis or chronic      │ Cirrhosis chronic active hepatitis or chronic      │
│ persistent hepatitis                               │ persistent hepatitis                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients who are currently receiving prasugrel     │ Patients who are currently receiving prasugrel     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ No concurrent use of isoniazid labetolol           │ No concurrent use of isoniazid labetolol           │
│ trovafloxacin tolcapone and felbamate              │ trovafloxacin tolcapone and felbamate              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ No concurrent use of other investigational drugs   │ No concurrent use of other investigational drugs   │
│ or antineoplastic therapies                        │ or antineoplastic therapies                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Patients with impaired cardiac function or         │ Patients with impaired cardiac function or         │
│ clinically significant cardiac diseases            │ clinically significant cardiac diseases            │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have minimum age of 18 Years │
╘═══════════════════════════════════╛